Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12873856 | 1.00 | ACE (0.56) | ACETAAR1MEN1KMT2ACTSB | |
| SCHEMBL23845056 | 0.82 | CYP3A4 (0.40) | ACETAAR1MEN1KMT2ACTSB | |
| SCHEMBL22112308 | 0.82 | TAAR1 (0.47) | ACETAAR1CTSB | |
| SCHEMBL18435256 | 0.81 | SIGMAR1 (0.46) | TAAR1MEN1KMT2ASIGMAR1SLC18A2 | |
| SCHEMBL1970032 | 0.81 | TAAR1 (0.53) | ACETAAR1MEN1KMT2ACTSB | |
| SCHEMBL6852338 | 0.81 | TAAR1 (0.53) | ACETAAR1MEN1KMT2ACTSB | |
| SCHEMBL2920753 | 0.81 | TAAR1 (0.53) | ACETAAR1MEN1KMT2ACTSB | |
| SCHEMBL10024808 | 0.81 | ACE (0.52) | ACETAAR1MEN1KMT2ACTSB | |
| SCHEMBL1741997 | 0.80 | NPC1 (0.60) | ACECTSBCAPN1CTSKCTSL | |
| SCHEMBL10024819 | 0.79 | ACE (0.48) | ACETAAR1MEN1KMT2ACTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861581-B9 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8106007-B2 | Having affinity to antithrombin III; improved pharmacokinetic properties when compared to the original polypeptides | N.V. ORGANON (NL) | 2012-01-31 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20080139459-A1 | Conjugates A Polypeptide And A Pentasaccharide | N.V. ORGANON (NL) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | ACE 446/4885TAAR1 1638/4885MEN1 3856/4885 |
| US-20080139459-A1 | Conjugates A Polypeptide And A Pentasaccharide | SERPINC1, F13A1, F13B | ACE 1093/4885TAAR1 4049/4885MEN1 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.